BRAF and EGFR mutations targeted drugs cocktail would evasion against new successful protein molecule-PLX4032-vemurafenib with colon cancer, said Dutch researchers.

This article is a few hours worked. Lookup, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.

27 January 2012: Source: Nature

A mutation in the BRAF (V600Egene) melanoma patients can be successful at best smallreason by a PLX4032(molecule-vemurafenib)- as medicine. There is known that at bowel cancer a portion of patients with the same mutation (BRAF gene V600E) a role in the emergence of such form of bowel cancer. However, these patients have a poor prognosis and studies point out that the so far mentioned means no or hardly contributes to the control over this form of bowel cancer. Darmkanker prove to have an escape route which cells stimulated by the molecular vemurafenib, says René Bernards, leader of a research that is done in the NKI-Anthonie van Leeuwenhoek hospital. The researchers did laboratory tests and animal tests with darmkanker cells in combination with vemurafenib. They then analyzed the piece by piece production of all proteins that are involved in cell growth and cell death. Ultimately proved that only the protein with EGFR (epidermal growth factor receptor) made sure that tumor cells survive despite the knden vemurafinib. In the NKI, they want to quickly set up a study with darmkanker patients who receive both the combinatiebehandleing than a BRAF mutation as the EGFR. From the abstract of vemurafinib respectively Nature, I understand that this can be or Tarceva Iressain combination with.

Here the abstract from Nature where, if you also the full study report click here against payment in can see

Drug combination of BRAF and EGRF inhibitors can mean successful treatment for certain forms of colon cancer

Unresponsiveness or colon cancer to BRAF (V600E) inhibition through feedback activation or EGFR

href = 3 > "http://www.nature.com/nature/journal/vnfv/ncurrent/full/nature10868.html#a2", 2
  • 1 René Bernards&
    • Journal name:
    Nature
    Year published:
    (2012)
    DOI:
    doi: 10.1038/nature10868
    Inhibition of the oncoprotein BRAF (V600E) by the small-molecule drug PLX4032 (vemurafenib) is highly1effective in the treatment of melanoma. However, BRAFharbouring the colon cancer patients (V600E) same oncogenic lesion have poor prognosis and show only a very limited response to this drug2 3 4,,. To investigate the cause of the BRAFPLX4032 limited therapeutic effect or (V600E) in mutant colon tumours, here we performed an RNA interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF (V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF (V600E) inhibition. BRAFWe find in (V600E) multiple mutant colon cancers that inhibition or EGFR by the antibody drug cetuximab or the small-molecule drug gefitinib or erlotinib is strongly synergistic with BRAF (V600E) in vitro inhibition, both in vivoand. Mechanistically, we find that BRAF (V600E) inhibition causes a rapid feedback activation or EGFR, which supports continued proliferation inhibition in the presence of BRAF (V600E). Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, EGFR ectopic expression or we find that in melanoma cells is sufficient to cause resistance to PLX4032. BRAFOur data suggest that (V600E) mutant colon cancers (approximately 8 – 10% of all colon
    cancers2 3 5,,), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.

    Figures at a glance

    left
    1. Figure 1: EGFR inhibition confers sensitivity to BRAF (V600E) inhibition in colon cancer.

      b a, CRC, but not melanoma cells harbouring the BRAF mutation are resistant to treatment PLX4032 (V600E). a, Short-term growth-inhibition assay or a cell line panel consisting of CRC (VACO432, SNU-C5, HT29, KM20 and WiDr) and melanoma (A375) cells. Cells were treated with increasing concentrations or PLX4032 for 72 h, and cell viability was determined using CellTiter- Blue by measuring the absorbance at 540 nm in a microplate reader. ErrorBars show data ± standard error. Means were derived from (n = 4) four replicates. b, Long-term colony formation assay or CRC (VACO432, KM20 and WiDr) and melanoma (A375) cells. Cells were grown in the absence or presence of PLX4032 at the indicated concentrations for 10 – 14 days. For each cell line, all dishes were fixed at the same time, stained and photographed. c, Schematic outline of the ' dropout ' RNAi screen for enhancers or PLX4032 sensitivity. Human kinome TRC shRNA library polyclonal virus was produced to infect WiDr cells, which were then left untreated (control) for 10 days or treated with 1 µ M PLX4032 for 18 days. After selection, shRNA inserts from both populations were recovered by polymerase chain reaction (PCR) and identified by deep sequencing (deepseq). d, Representation of the relative abundance of the shRNA barcode sequences from cdepicted the shRNA screen experiment in. Y-axis shows The enrichment (relative abundance or PLX4032 treated/untreated) x-axis shows intensity and the (average sequence reads in untreated sample) or each shRNA. Among the 22 top shRNA candidates (more than fivefold depleted by PLX4032 treatment and more than 300 reads in the untreated condition (as indicated by the red dashed lines) shEGFR , three independent vectors (in red) were identified.

    f e, EGFR , Three independent shRNAs targeting enhance response to PLX4032. e, The functional phenotypesEGFR or non-overlapping sh vectors are indicated by colony formation assay in 1 µ M PLX4032. The pLKO vector was used in the experiment control (Ctrl). The cells were fixed, stained and photographed after 14 days. f, The level or knockdown or EGFR by each of the shRNAs was measured by examining the EGFR protein levels by western blotting.

  • Figure 2: Functional and biochemical interaction between BRAF and EGFR inhibition in colon cancer.

    a, Synergistic response or WiDr cells to the combination of EGFR and BRAF (V600E) inhibitors. WiDr cells were cultured in increasing concentrations or BRAF inhibitor PLX4032 alone, EGFR inhibitors cetuximab ( ml 1.25− 1mg) ( µ M 0.125) gefitinib or alone, or their combinations. The cells were fixed, stained and photographed after 18 days. b, Resistance to BRAF (V600E) in cells is mediated through feedback inhibition WiDr activation or EGFR. Biochemical responses or WiDr cells treated with PLX4032, cetuximab, gefitinib or or their combinations, were documented by western blot analysis. H at 6 Cells were harvested after drug treatment. BRAF (V600E) inhibition results in strong upregulation or Tyr 473 1068 p-EGFR and Ser-phosphorylated AKT (p-AKT), which is abrogated by EGFR inhibitors. Furthermore, combination treatments result in complete inhibition or phosphorylated MEK (p-MEK) and phosphorylated ERK (p-ERK). Heat shock protein 90 (HSP90) served as a control. d c, MEK, or BRAF to mediate the feedback regulation acts downstream of EGFR in BRAF mutant CRC cells. c, MEK inhibitor activates p-EGFR to the same extent as PLX4032. Activation of EGFR in cells treated with PLX4032 WiDr, VACO432 and KM20 AZD6244 or for 6 h was analysed by western blot. d MEK-DD , prevents the activation or EGFR by PLX4032. Western blot analysis of EGFRPURO pBabe-WiDr in cells expressing (pBp) MEK-DD vector control or for treated with PLX4032 e1 h., Western blot analysis showing that suppression or CDC25C by two independent shRNA vectors results in elevated levels of p-EGFR WiDr in cells. f, PLX4032 treatment leads to a reduced activation or CDC25C. Feedback regulation of cells treated with PLX4032 CDC25C and EGFR in VACO432 for 1 h were documented by western blot

    • analysis.

  • Figure 3: Correlation between EGFR levels and response to BRAF inhibition in melanoma and CRC.

    a, Western blot analysis or p-EGFR and EGFR levels in a panel or BRAF (V600E) mutant cell lines from melanoma, CRC and thyroid cancer. HSP90 served as a control. b, High levels of EGFR expression in tumour types (V600E) correlate with PLX4032 harbouring BRAF mutations resistance. Short-term growth-inhibition assays or a cell line panel consisting of thyroid cancer (HTC-C3 and 8505C), CRC (OXCO-1, COLO741 and WiDr) and melanoma (A375) cells. Cells were treated with increasing concentrations or PLX4032 for 72 h, and cell viability was determined using CellTiter- Blue by measuring the absorbance at 540 nm in a microplate reader. ± Standard error bars Error show dates. Means were derived from (n = 4) four replicates. c, Long-term colony formation assay or thyroid cancer (8505C), CRC (OXCO-1, COLO741 and WiDr) and melanoma (A375) cells. Cells were grown in the absence or presence of PLX4032 at the indicated concentrations for 10 – 14 days. For each cell line, all dishes were fixed at the same time, stained and photographed. d, Ectopic EGFR expression confers resistance to PLX4032, but not to the combination of PLX4032 and gefitinib in A375 melanoma cells. PURO A375 cells expressing pBabe-or EGFR (pBp) vector control were cultured ( µ M 5) in PLX4032 gefitinib ( µ M 2.5), or their combination. The cells were fixed, stained and photographed after 7 (untreated or gefitinib) or 9 (PLX4032 alone or in combination with gefitinib) days. e, Western blot analysis or p-EGFR and total EGFR levels in cells described above. HSP90 served as a control. f, Synergistic response or thyroid cancer HTC-C3 cells to the combination of EGFR and BRAF (V600E) inhibitors. HTC-C3 cells were cultured in increasing concentrations or PLX4032 alone, cetuximab ( ml 1.25− 1mg) ( µ M 2.5) gefitinib or alone, or their combinations. The cells were fixed, stained

    • and photographed after 18 days.

  • Figure 4: EGFR and synergize to induce apoptosis BRAF (V600E) inhibitors or CRC cells and to suppress CRC tumour growth in a xenograft model.